PERSPECTIVES

1049 Chemoprevention Meets Glucose Control
Jeffrey A. Engelman and Lewis C. Cantley
See article p. 1066

1053 DNA Methylation Markers for Prostate Cancer with a Stem Cell Twist
Carmen Jerónimo and Manel Esteller
See article p. 1084

1056 Screening for Oral Premalignancy and Cancer: What Platform and Which Biomarkers?
Mark W. Lingen
See article p. 1093

REVIEW

1060 Metformin and Other Biguanides in Oncology: Advancing the Research Agenda
Michael Pollak

1066 Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis
Regan M. Memmott, Jose R. Mercado, Colleen R. Maier, Shigeru Kawabata, Stephen D. Fox, and Phillip A. Dennis
See perspective p. 1049

1077 Metformin Suppresses Colorectal Aberrant Crypt Foci in a Short-term Clinical Trial
Kunihiro Hosono, Hiroki Endo, Hirokazu Takahashi, Michiko Sugiyama, Eiji Sakai, Takashi Uchiyama, Kaori Suzuki, Hiroshi Iida, Yasunari Sakamoto, Kyoko Yoneda, Tomoko Koide, Chikako Tokoro, Yasanobu Abe, Masahiko Inamori, Hitoshi Nakagama, and Atsushi Nakajima

1084 Global Reactivation of Epigenetically Silenced Genes in Prostate Cancer
Ilsya Ibragimova, Inmaculada Ibáñez de Cáceres, Amanda M. Hoffman, Anna Potapova, Essel Dulaimi, Tahseen Al-Saleem, Gary R. Hudes, Michael F. Ochs, and Paul Cairns
See perspective p. 1053

1093 Endothelin Receptor Type B Gene Promoter Hypermethylation in Salivary Rinses Is Independently Associated with Risk of Oral Cavity Cancer and Premalignancy
Kavita Malhotra Pattani, Zhe Zhang, Semra Demokan, Chad Glazer, Myriam Loyo, Steven Goodman, David Siddransky, Francisco Bermudez, Germain Jean-Charles, Thomas McCaffrey, Tapan Padhya, Joan Phelan, Silvia Spivakovsky, Helen Yoo Bowne, Judith D. Goldberg, Linda Rolnitzky, Miriam Robbins, A. Ross Kerr, David Sirois, and Joseph A. Califano
See perspective p. 1056

1104 UV Radiation Inhibits 15-Hydroxyprostaglandin Dehydrogenase Levels in Human Skin: Evidence of Transcriptional Suppression

1124 Disruption of Androgen and Estrogen Receptor Activity in Prostate Cancer by a Novel Dietary Diterpene Carnosol: Implications for Chemoprevention
Jeremy J. Johnson, Deeba N. Syed, Yeewseo Suk, Chenelle R. Heren, Mohammad Saleem, Imtiaz A. Siddiqui, and Hasan Mukhtar

1124 Low-Carbohydrate Diets and Prostate Cancer: How Low Is “Low Enough”?
Elizabeth M. Masko, Jean A. Thomas II, Jodi A. Antonelli, Jessica C. Lloyd, Tameika E. Phillips, Susan H. Poulton, Mark W. Dewhirst, Salvatore V. Pizzo, and Stephen J. Freedland


Vascular Endothelial Growth Factor Receptor 2–Targeted Chemoprevention of Murine Lung Tumors

Vijaya Karoor, Mysan Le, Daniel Merrick, Edward C. Dempsey, and York E. Miller

A Dominant-Negative c-jun Mutant Inhibits Lung Carcinogenesis in Mice

Jay W. Tichelaar, Ying Yan, Qing Tan, Yian Wang, Richard D. Estensen, Matthew R. Young, Nancy H. Colburn, Hulian Yin, Colleen Goodin, Marshall W. Anderson, and Ming You

Synthetic Progestins Differentially Promote or Prevent 7,12-Dimethylbenz(a)anthracene–Induced Mammary Tumors in Sprague-Dawley Rats

Indira Benakanakere, Cynthia Besch-Williford, Candace E. Carroll, and Salman M. Hyde

Resveratrol Modulates Drug- and Carcinogen-Metabolizing Enzymes in a Healthy Volunteer Study


Genome-Wide Catalogue of Chromosomal Aberrations in Barrett’s Esophagus and Esophageal Adenocarcinoma: A High-Density Single Nucleotide Polymorphism Array Analysis

Jian Gu, Jaffer A. Ajani, Ernest T. Hawk, Yuanqing Ye, Jeffrey H. Lee, Manoop S. Bhutani, Wayne L. Hofstetter, Stephen G. Swisher, Kenneth K. Wang, and Xifeng Wu

Molecular Alterations Associated with Sulindac-Resistant Colon Tumors in Apc(min) Mice

Emily J. Greenspan, Frank C. Nichols, and Daniel W. Rosenberg

Enhanced Induction of Mucin-Depleted Foci in Estrogen Receptor β Knockout Mice

Diana Saleiro, Genoveva Murillo, Dennis B. Lubahn, Levy Kopelovich, Kenneth S. Korach, and Rajendra G. Mehta

Mitochondrial DNA Mutation in Normal Margins and Tumors of Recurrent Head and Neck Squamous Cell Carcinoma Patients

Santanu Dasgupta, Rachel Koch, William H. Westra, Joseph A. Califano, Patrick K. Ha, David Sidransky, and Wayne M. Koch

ABOUT THE COVER

The diagram reflects potential and known effects of the diabetes drug metformin (one of the most commonly used drugs in the world) on important molecular pathways of carcinogenesis in cells. The mammalian target of rapamycin (mTOR) exists in TOR complex 1 (TORC1) and TORC2. TORC1 controls cell growth through phosphorylating p70 S6 kinase (p70S6K) and 4E-binding protein 1 (4EBP1). Various inputs of TORC1 regulation appear to directly affect the TSC1–TSC2 complex, which controls activation of the Ras homologue enriched in brain (RHEB) protein that directly activates TORC1. Growth factor signaling (through phosphatidylinositol 3-kinase [PI3K]/Akt and extracellular signal-regulated kinase [ERK]/ribosomal S6 kinase [Rsk] signaling) and energy homeostasis (through AMP-activated protein kinase [AMPK]) directly phosphorylate TSC2. In vivo, metformin downregulates TORC1 possibly via both AMPK-dependent mechanisms and AMPK-independent mechanisms (dotted blue line from “Energy stress”) or via its effect of decreasing levels of circulating insulin and insulin-like growth factor (IGF), which decreases activation of the IGF-1 receptor (IGF-1R)/insulin receptor (IR), leading in turn to suppression of PI3K and Ras signaling. See articles by Memmott et al. (beginning on page 1066), Hosono et al. (beginning on page 1077), Pollak (beginning on page 1060), and Engelman and Cantley (beginning on page 1049) for more information.
Cancer Prevention Research

3 (9)


Updated version
Access the most recent version of this article at:
http://cancerpreventionresearch.aacrjournals.org/content/3/9

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.